Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial
This article was originally published in The Gray Sheet
Executive Summary
Novoste Corp. is considering further evaluation of its Beta-Cath radiation system using a longer source train and a smaller diameter catheter in conjunction with initial angioplasty treatment.
You may also be interested in...
Novoste Sees More Beta-Cath Placements, Looks To Exploit First Mover Lead
Novoste Corp. expects to place 220-280 Beta-Cath brachytherapy systems in top U.S. centers by the end of 2001, an increase from the company's previous guidance of 180-250 placements for the year.
Novoste Sees More Beta-Cath Placements, Looks To Exploit First Mover Lead
Novoste Corp. expects to place 220-280 Beta-Cath brachytherapy systems in top U.S. centers by the end of 2001, an increase from the company's previous guidance of 180-250 placements for the year.
Novoste 40 mm Seed Train Addresses Clinical Concern Over "Edge" Effect
Novoste plans to introduce into ongoing European and U.S. clinical trials this quarter a longer seed train for the Beta-Cath radiotherapy catheter system, which is intended to prevent possible restenosis at the edge of the treatment zone of a coronary vessel.